Please provide your email address to receive an email when new articles are posted on . In patients who underwent surgical bioprosthetic valve implantation or repair, early postoperative ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be ...
Elderly patients with atrial fibrillation (AF) who are at high risk of bleeding may benefit from a low 15-mg dose of edoxaban, regardless of their frailty status, a subanalysis of the ELDERCARE-AF ...
WASHINGTON, DC—In another negative result for a direct oral anticoagulant in the post-TAVI setting, edoxaban (Savaysa; Daiichi Sankyo) did not have an advantage over dual antiplatelet therapy (DAPT) ...
LISBON, Portugal—Use of uninterrupted edoxaban (Savaysa; Daiichi Sankyo) during catheter ablation for A-fib is associated with rates of thromboembolic and bleeding events that are low and comparable ...
Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...
HealthDay News — For patients with cancer-associated venous thromboembolism, oral edoxaban is noninferior to subcutaneous dalteparin for recurrent venous thromboembolism or major bleeding, according ...
BETHESDA, MD — The US Food and Drug Administration (FDA) has approved edoxaban (Savaysa, Daiichi-Sankyo), a factor Xa inhibitor, for the prevention of stroke and non–central-nervous-system (CNS) ...
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering from blood clots in the legs and lungs. NICE has issued a Final Appraisal ...
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
The Appraisal Committee considered evidence submitted by Daiichi Sankyo and a review of this submission by the Evidence Review Group (ERG). The primary source of evidence was ENGAGE AF‑TIMI 48, a ...
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non‑valvular atrial fibrillation with one or more risk factors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results